The immune function of B lymphocytes from 12 patients with nonneoplastic immunemediated diseases receiving chronic low-dose (2 mg/kg per d) cyclophosphamide (CY) was evaluated. There was a selective and differential suppressive effect of CY therapy on the various stages of the B cell cycle including activation, proliferation, and differentiation. The proliferative responses to Staphylococcus aureus Cowan strain I (SAC) and mitogenic concentrations of anti-mu were suppressed. In contrast, B cells that have been presumably activated in vivo proliferated with a normal pattern when exposed to B cell growth factor in vitro. Chronic low-dose CY therapy also suppressed B cell differentiation. Secretion of immunoglobulin by B cells following in vitro triggering with SAC and a T cell supernatant was suppressed in CY-treated patients. Moreover, differentiation of the large in vivoactivated B cells (which do not require an in vitro activation signal) in the presence of appropriate T lymphocyte supernatant was also suppressed. This selective suppression of B cell function at multiple points in the B cell cycle may be responsible for the efficacy of CY therapy in certain antibody and immune complex-mediated diseases.
Introduction
Cyclophosphamide (CY)' administered chronically in low doses has been used with increasing frequency and success in the treatment ofnonneoplastic diseases characterized by hyperreactivity ofthe immune system (1) (2) (3) . This therapeutic approach has been particularly effective in the treatment of a number of systemic vasculitic syndromes including Wegener's granulomatosis (4) , systemic necrotizing vasculitis (5) , and lymphomatoid granu-lomatosis (6) . Although a variety ofimmunomodulatory effects have been demonstrated in animal models after short-term highdose CY treatment protocols (7) (8) (9) (10) (11) , information on the effects of chronically administered low-dose CY on the immune system in man is limited (12) (13) (14) (15) (16) . Recently, we have demonstrated a clear-cut selective effect of CY therapy on mitogen-stimulated Ig production (16). In the present report, we evaluate the effect of chronic low-dose CY therapy on the distinctive phases ofthe B cell cycle.
Investigation in this and other laboratories has resulted in delineation of the sequential events in the human B cell activation cascade (17) (18) (19) (20) (21) . Using this model system, it has been demonstrated that resting B cells can be activated by a number ofinitial signals. Following activation, the B cells are then capable ofresponding to a number ofT cell-derived growth factors such as B cell growth factor (BCGF) or differentiation factors such as B cell differentiation factor (BCDF). In the present study, we demonstrate the selective effects of in vivo-administered CY therapy on distinct phases ofthese activation, proliferation, and differentiation processes.
Methods
Subjects. 12 patients, 4 men and 8 women ranging in age from 14 to 57 yr, were studied while being treated with oral CY as inpatients under the systemic vasculitis protocol at the National Institutes ofHealth. Clinical, laboratory, and therapeutic parameters of these patients are summarized in Table I . All patients were in sustained clinical remission as previously defined (4, 5) at the time the studies were performed. All patients had a urinary creatinine clearance of > 60 ml/min at the time of study. 5 ofthe 12 patients were also receiving alternate-day prednisone therapy. Blood from these individuals was drawn 48 h after the last dose of prednisone to avoid corticosteroid-related effects (T. R. Cupps' and A. S. Fauci, unpublished observations, and ref. 16 ). Patients were initially treated with CY (2 mg/kg per d) orally as a single daily dose with subsequent adjustments of the CY dosage to avoid a peripheral leukocyte count below 3,000 cells/mm3. In addition, seven patients were studied at varying times after successfully completing a therapeutic trial of CY therapy. The clinical, laboratory, and therapeutic parameters of these latter patients are summarized in Table II . Patients were studied between 1.5 and 132 moaftercompletion oftheCYtherapy. 13 In some experiments, the TCD fractions were further monocyte depleted as described previously (23) , with slight modification. Briefly, UF mononuclear cells were suspended in 0.2% FCS in RPMI and incubated at 370C for 30 min to allow adherence to 4-mm glass beads (Kimble Div., Owens-Illinois Inc., Toledo, OH). AET-SRBC rosetting cells were then depleted as described above, and the remainder of cells were incubated over Sephadex G-10 columns with 1% FCS in RPMI 1640 for 15 min at 370C. The number of surface immunoglobulin-positive cells (sIg') ranged between 70 and 85%. The nonadherent cells that eluted from the column were < 5% esterase positive and were used as monocytedepleted B cells.
In the studies examining surface markers of B cell activation and cell size changes, monocyte depletion was accomplished by L-leucine methyl ester depletion as previously described in detail (24) . These B cell preparations contained 55-75% sIg' cells and had < 1% esterasepositive cells.
Mitogens Generation ofPWM-stimulated supernatant (PWM-SN). The PWM-SN was prepared from AET rosette-positive cells (2 X 106/ml) by culturing the cells in 10% FCS in RPMI 1640 with 2 mM glutamine in 15-mm diameter plastic wells in a final PWM concentration of 1:200 in a final volume of 2 ml per well. The supernatants were harvested after 48 h. Control supernatants were obtained in a similar fashion except that PWM was added after the supernatant was harvested. Both PWM-induced and control supernatants were aliquoted and stored at -20°C until used.
BCGF. Monoclonal BCGF from a human T-T cell hybridoma was used as previously described by Butler et al. (20) . Determination min at 4°C. The cells were washed twice and resuspended in 0.5 ml of wash solution for counting. The cells were analyzed by using a fluorescence-activated cell sorter (FACS II; Becton-Dickinson & Co.). The data were analyzed using a PDP 11/34 computer (Digital Equipment Corporation, Landover, MD). The FMF analysis was performed by using logarithmic amplification of the gain.
Monocyte-and T cell-depleted B lymphocyte preparations were evaluated for presence ofcell surface markers of activation. Two monoclonal antibodies 4F2 (26, 27) and SE9 (28) (29) . Two protocols to stimulate TCD cell fractions to develop into ISC were employed. In the first assay, 5 X 101 TCD cells were cultured in 12 X 75-mm plastic tubes in the presence of 10% FCS, RPMI 1640 with 2 mM glutamine, gentamicin 0.1% with SAC 1:50,000 (vol/vol) final concentration as previously described (18) . On the second day after the culture was set up, 0.5 ml of the culture supernatant was removed and replaced with 0.5 ml of MLR-SN. After 6 d, a PFC assay was performed on the cultured cells to determine the number of ISC. In the second assay, 5 X 101 TCD cells were cultured in 10% FCS, RPMI 1640 with 2 mM glutamine, 0.1% gentamicin, and 0.5 ml PWM-SN to a total volume of 1 ml in a 10 X 75-mm plastic tube (30) . These cultures were also harvested after 6 of monocytes in the patient (32±4%) and control group (34±6%) were maintained at a similar level to avoid the nonspecific suppressive effect ofhigh percentages ofmonocytes. Decreasing the number of monocytes to < 5% as determined by nonspecific esterase-positive cells did not reconstitute the suppressed response (Table III) . The next series of experiments were performed to determine if the decreased blastogenic responses of patient B cells were due to alterations in the time kinetics of the response or shifts in the dose response curve of the mitogens (SAC and anti-st) employed. It was clearly demonstrated that the suppressed B cell mitogenic responses were not due to changes in the time kinetijs (Fig. 1) or the dose response curves (Fig. 2) (Fig. 3 A) .
Following in vitro stimulation with anti-M for 36 h in cultures, normal peripheral blood B cells enlarge, but B cells from CYtreated patients fail to enlarge further (Fig. 4 B) . To determine the significance of the in vivo enlargement of B cells from CYtreated patients, cell surface markers of activation, 4F2 and SE9 (31) , were evaluated. We have previously demonstrated that following in vitro activation with SAC or anti-a, human B cells not only enlarge but also express the cell surface markers of activation, 4F2 and 5E9 (31) . Despite the in vivo enlargement, neither 4F2 (normal 2.0±0.87; CY-treated 1.7±0.67, n = 4) nor 5E9 (normal 3.1±1.3; CY-treated 5.6±1.3, n = 4, P . 0.18) expression was significantly increased on the B cells from CYtreated patients.
Proliferative response to BCGF is unaltered by CY therapy.
We have previously demonstrated that a subset of normal peripheral blood B cells will proliferate in vitro when cultured with BCGF in the absence of any additional in vitro activation signals (21) . Presumably, this BCGF-responsive subset of B cells from normal individuals has received some in vivo activation stimulus.
If peripheral blood B cells are separated by size, the BCGFresponsive cells are enriched in the larger cell fractions. To evaluate for the presence of BCGF-responsive subsets, B cells from CY-treated patients were cultured with monoclonal BCGF in the absence of any additional in vitro activating signal (Fig. 4) . The response to BCGF alone was similar in normals and patients. This observation suggests that patients being treated with CY have a subset ofB cells in the peripheral blood similar to normals that has received some in vivo stimulus to activate them to a BCGF responsive state.
CY therapy suppresses B cell differentiation. B cell differentiation following SAC stimulation as measured in a PFC assay was suppressed during treatment with CY (Fig. 5) . This was seen in UF mononuclear cells. However, because it was unclear whether the suppression of differentiation was due to a defect at the B cell level or due to a lack of available T cell-derived differentiation factors, the following experiments were performed. Normal or patient B cells were cultured in the presence or absence of exogenous T cell-derived differentiation factors provided by an MLR-SN, a standard source of BCDF (18) . As can be seen (Fig. 5) , neither normal nor patient B cells alone responded to SAC with differentiation and Ig secretion. However, when MLR-SN was provided, normal B cells responded with differentiation whereas patient B cells still did not secrete Ig.
Thus, the defect in differentiation in CY-treated patients cannot be explained by a lack of T cell-derived differentiation factor and is indeed at the level of the B cell itself.
To further evaluate the potential relationship between the defective B cell differentiation in CY-treated patients and the ability ofthese B cells to proliferate in response to growth factors, another assay system was employed. Because we had previously shown that patients have decreased proliferative responses to SAC (Table III) , we stimulated patient and normal B cells (TCD suspensions) with a supernatant from PWM-stimulated normal T lymphocytes (PWM-SN). We had previously shown that when (Fig. 6 A) .
However, despite the presence of activated B cells that can proliferate normally, the ability of these preactivated B cells to differentiate is markedly suppressed (Fig. 6 B) . The failure of the B cells from patients treated with CY to differentiate does not appear to be the result of a shift in the kinetic response curve (Fig. 7) . Data from one study is shown. A similar pattern was seen in a second study (data not shown). A similar defect in differentiation was noted in CY-treated patients when intracy- Recovery ofB cellfunctionfollowing cessation ofCYtherapy.
The results of B cell functional assays in seven patients studied between 1.5 and 132 mo, after successfully completing a course of CY therapy are summarized in Table IV . The rate at which the B cell function recovers following cessation of CY therapy may vary. The B cell function of the first patient in Table IV restored except for a minimal suppression ofthe anti-M stimulated proliferative response. The second patient in Table IV , studied 10 mo following completion ofCY therapy, has normal functions except for a marked suppression of SAC-stimulated PFC responses. All patients studied more than a year after successful completion ofthe CY therapy had full recovery ofB cell function. The studies presented in Table IV indicate that according to the parameters examined, B cell function returned to normal following cessation of CY therapy.
Discussion
The present study demonstrates the multifaceted suppression of B cell function in patients with immunologically mediated nonneoplastic diseases receiving chronic low doses of CY. There is a selective suppressive effect of CY therapy on discrete stages of the B cell cycle including both proliferation and differentiation. but unaltered in patients with vasculitic diseases (13, 15) treated with CY. Blastogenic responses to T cell antigens (13, 14) and induction ofdelayed hypersensitivity responses to a new antigen (14) can be suppressed during chronic therapy with CY. In contrast, impairment of concanavalin A-inducible suppressor activity and potentiation of delayed-type hypersensitivity responses to a new antigen have been reported (32, 33) several days after a single dose of CY. Active metabolites of CY augment human natural killer cell activity in vitro (34) . The T helper cell function such as the ability to provide "help" in T cell-dependent PWMstimulated Ig production is unaltered by chronic CY therapy (16). Although Ig production may be augmented shortly after initiation of CY therapy (33) , B cell function is suppressed by chronic low-dose CY therapy. Both reduction of serum Ig levels (12, 14) and suppression ofin vitro Ig production following PWM stimulation (16) have been reported. Exposure to CY metabolites that are active in vitro also suppresses B cell function (35) . In this report, we have evaluated the effects of CY therapy on the different phases of the B cell cycle from proliferation to differentiation. In patients treated with chronic low doses of CY, the response to the B cell mitogens SAC or high concentrations of anti-is is decreased. There are several potential explanations for the suppressed responses. Although the total number of lymphocytes is decreased in patients receiving CY, the percent of (37) .
In vitro Ig production is also suppressed by CY therapy. The Ig production in B cell preparations stimulated with SAC in the presence of a T cell-derived differentiation signal (MLR-SN) is suppressed. As previously noted, the earlier events of SAC-stimulated activation and proliferation are also substantially suppressed. Consequently, the low levels of Ig production could be related to either suppressed activation/proliferation, altered differentiation, or a combination ofthe two activities. These observations provide new insights into the mechanisms of chronic low-dose CY-mediated immunosuppression and should provide an additional scientific basis for the rational uses of this potent and effective immunosuppressive agent.
